Navigation Links
KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births
Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive options agreement with Cedars-Sinai Medical Center to research a new blood test that could predict the risk of premature births early in pregnancy – or even before women become pregnant. Preterm delivery (PTD) is the leading cause of infant mortality in the world, causing up to 85 percent of all newborn deaths. KellBenx' worldwide license for Cedars-Sinai's diagnostic biomarker technology is the first step towards developing a marketable, minimally invasive test that can predict PTD and allow patients and doctors to make informed decisions about pregnancy in advance.

PTD occurs in about one-eighth of all pregnancies in the United States – more than a half million cases a year – but the primary current diagnostic testing for PTD risk is used only in the third trimester, to predict whether the patient will go into labor within the next two weeks.

"There is currently no test to predict the risk of PTD in future pregnancies of women who are not yet pregnant, and there is a tremendous need for such a test to identify women at high risk," said Hassan Bennani, MD., CEO of KellBenx. "With this agreement, KellBenx can begin the research process to turn this biomarker technology into a simple blood test that will help physicians focus on preventative strategies in these women and improve pregnancy outcomes. This is early-stage technology, but it has exciting possibilities for potentially reducing infant mortality."

The technology consists of a triple assay of biomarkers  that can measure a blood sample obtained from the prospective mother either before pregnancy or in the early stages to identify the potential for PTD.  The test could be repeated multiple times during pregnancy to track potential changes in risk as the pregnancy progresses.

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631.643.2614 or visit www.kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WNDM Secures Additional International Sales; $150 K in New Orders for 2011
2. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
3. ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
4. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
5. SeraCare Life Sciences Secures $20 Million Credit Facilities
6. Medizone International Secures $10,000,000 Funding Commitment
7. aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. SPO Medical Secures Agreement in Sleep Apnea Market
10. Biolaxy Secures IND Approval for Oral Insulin
11. Osteotech Secures 10-Year Tissue Supply Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Oakland, California (PRWEB) , ... February 04, 2016 ... ... Artificial Intelligence (AI) and leading supplier of Semantic Graph Database technology has been ... Graph Database Products ” by Corporate America Magazine. , “At Corporate America, it’s ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... Denver, Colorado (PRWEB) , ... February 03, 2016 ... ... to hospitals, has established a new office dedicated to the North American healthcare ... provide turnkey solutions to healthcare facilities. The company will provide new pneumatic ...
Breaking Biology Technology:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
Breaking Biology News(10 mins):